A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Ascentage Pharma Group Inc.
Study ID
NCT04354727
Phase
PHASE1/PHASE2
Status
Withdrawn

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • APG-1252 — DRUG
    infusion once weekly
  • Ruxolitinib — DRUG
    taken orally twice a day

Study Details

The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.

Key Dates

Start date
Dec 15, 2020
Status verified
Jul 2022
Primary completion
Dec 15, 2022
Completion
Jun 15, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: APG-1252
  • Experimental: APG-1252 + Ruxolitinib

Primary Outcome Measure

Dose-limiting toxicity (DLT) rate at each dose level [ Time Frame: 28 days ]

Locations (2)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer CenterGilbertArizona85234-
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Gilbert, AZ

By research site
Banner MD Anderson Cancer Center· Gilbert, AZUniversity of Texas MD Anderson Cancer Center· Houston, TX

Related Studies